| 瑞苏伐他汀遗传药理学研究进展 |
| |
| 引用本文： | 鲍美华,张轶雯,程琳,周宏灏.瑞苏伐他汀遗传药理学研究进展[J].金属学报,2013,18(2):234-240. |
| |
| 作者姓名： | 鲍美华 张轶雯 程琳 周宏灏 |
| |
| 作者单位： | 1.中南大学临床药理研究所,长沙 410078,湖南;2.长沙医学院药学系,长沙 410219,湖南 |
| |
| 基金项目： | 重大新药创制专项临床前药物代谢动力学技术平台资助项目(20092X0950L032,2009ZX09304-003); 湖南省教育厅科学研究项目(11C0152) |
| |
| 摘 要： | 胆固醇水平升高是动脉粥样硬化发病的主要原因。瑞苏伐他汀为临床常用的抑制胆固醇合成的药物,其药动学和药效学存在显著个体差异。药物转运体、药物代谢酶、药物靶点的遗传多态性对瑞苏伐他汀的体内代谢和临床疗效个体差异具有重要作用。本文阐述了药物转运体、细胞色素P450酶和其他相关基因的遗传多态性对瑞苏伐他汀药动学和药效学的影响,为临床制定个体化用药方案提供参考。
|
| 关 键 词： | 动脉粥样硬化 瑞苏伐他汀 遗传药理学 转运体 |
| 收稿时间： | 2012-04-24 |
| 修稿时间： | 2012-04-24 |
Pharmacogenetic progress of rosuvastatin in atherosclerosis |
| |
| BAO Mei-hua,ZHANG Yi-wen,CHENG Lin,ZHOU Hong-hao.Pharmacogenetic progress of rosuvastatin in atherosclerosis[J].Acta Metallurgica Sinica,2013,18(2):234-240. |
| |
| Authors: | BAO Mei-hua ZHANG Yi-wen CHENG Lin ZHOU Hong-hao |
| |
| Affiliation: | 1.Institute of Clinical Pharmacology, Central South University, Changsha 410078, Hunan, China;2.Department of Pharmacy, Changsha Medical University, Changsha 410219, Hunan, China |
| |
| Abstract: | Hypercholesterolemia plays a key role in the initiation and progression of atherosclerosis. Rosuvastatin is widely used to prevent cholesterol synthesis. There are great individual differences in pharmacokinetics and pharmacodynamics characters in clinical use of rosuvastatin.Pharmacogenetics indicates that genetic polymorphisms of drug transporters, metabolizing enzymes, and receptors play very important roles in the metabolism and therapeutical efficacy of rosuvastatin. In this review, we summarized the effects of genetic polymorphisms of certain drug transporters, CYP450 enzymes or other related genes on the pharmacokinetics and pharmacodynamics of rosuvastatin.It will provide part of the basis for personalized medicine of rosuvastatin. |
| |
| Keywords: | Atherosclerosis Rosuvastatin Pharmacogenetics Transporter |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
|
